Effect of sodium bisulphate on the stability of octreotide acetate: compatibility study with dexamethasone injection

Kouichi Tanabe1, Jun Ohkubo1, Tomoaki Ikezaki1, Shohei Kitayama2, Yuki Tsuneda2, Atsumi Nitta3, Lisa Imamura3, Hideto To3, Masanari Shimada4, Nozomu Murakami4 and Hidenori Kitazawa1

1) Department of Pharmacy, Saiseikai Takaoka Hospital, 2) Department of Medical Pharmaceutics, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 3) Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 4) Department of Surgery, Saiseikai Takaoka Hospital

Effect of sodium bisulphate on the stability of octreotide acetate 177

Background: Although several dexamethasone phosphate preparations are commercially available and frequently administered with octreotide acetate, their compatibility remains unknown. Aim: We investigated the effect of pH and sodium bisulphate on the stability of octreotide acetate. Measurement design: Octreotide acetate percentage was measured 3 and 10 days after it was mixed with 2 dexamethasone phosphate preparations containing different concentrations of sodium bisulphate as an additive, and in one that did not contain sodium bisulphate. Solutions were also analysed after they were prepared using phosphate buffer to achieve pH values of 4.0, 7.0, and 9.0. The initial octreotide acetate concentration was 41.7 g/mL. High-performance liquid chromatography was used for measurement. Results: The octreotide acetate percentage in the mixture with dexamethasone phosphate without sodium bisulphate was maintained at ≥95% for up to 10 days. However, mixing octreotide acetate with the other 2 agents resulted in a significant decrease to 85%. The octreotide acetate percentage was <90% after sodium bisulphate−containing solution was stored at room temperature under light−protected conditions for 3 days. The percentage of octreotide acetate in the pH 7.0 solution was <90% three days after preparation; however, in the pH 4.0 solution, it was maintained at ≥95% for up to 10 days. Conclusions: Our results suggest that octreotide acetate is hydrolysed in the presence of sodium bisulphate, leading to a decrease in the percentage of octreotide acetate in the solution, which can be avoided using sodium bisulphate−free dexamethasone phosphate preparations.

Key words: octreotide, dexamethasone, sodium bisulphate, compatibility, pH

Introduction

Octreotide acetate (OCT) is a cyclic octapeptide containing a disulphide bond that is necessary for the physiological activities of the molecule (Fig. 1)1−7. It is a key drug for cancerous, peritonitis related obstruction of the digestive tract7, 8. In terminal cancer patients with obstruction of the digestive tract, early combination therapy with OCT and dexamethasone sodium phosphate (DEX) reduces oedema of the digestive tract, decreasing digestive tract pressure and relieving obstruction9. These 2 agents are frequently administered together for palliative care.

Sodium bisulphate (SBS) is an additive contained in some DEX injection preparations and has been reported to inactivate physiologically active peptides through peptide hydrolysis or disulphide bond cleavage9, 10. However, this change cannot be evaluated visually. In addition, no study has examined the compatibility of OCT with DEX injection in the absence of SBS. Whether DEX preparations contain SBS differs between countries. In Japan, SBS containing and SBS-free DEX preparations are both commercially available.

It has been reported that continuous subcutaneous administration of OCT and other drugs in a mixture is useful for the patients who cannot take the drugs orally10. Currently, limited information is available regarding the stability of OCT mixed with other drugs including DEX injection preparations, excluding diamorphine hydrochloride11; this information is necessary for estimating compatibility. In combination therapy with OCT and DEX, recommendations specify that DEX should be subcutaneously administered separately from OCT12. However, given that frequent punctures reduce quality of life (QOL), identifying the causes of incompatibility and investigating methods that may allow them to be injected as a mixture may be beneficial to...
patients. In this study, both SBS containing and SBS free DEX injection preparations were mixed with OCT, and the concentration of OCT was quantified using high performance liquid chromatography (HPLC) to evaluate the effect of SBS on the stability of OCT mixed with DEX injection preparations. The effect of pH on the stability of the mixtures was also investigated because of an important factor influencing a hydrolysis reaction[5].

Methods

1. Materials

OCT was obtained from Sigma-Aldrich Japan (Japan). Sandostatin® for subcutaneous (S.C.) injection (100 μg/mL) was purchased from Novartis Pharma Co., Ltd. (Japan). For the evaluation of DEX products with different SBS concentrations, Dexart® injection (SBS 2 mg/mL), Decadron® injection (SBS 0.5 mg/mL), and Orgadrone® injection (SBS-free; DEX SBS 0) solutions were purchased from Fuji Pharma Co. Ltd. (Japan), MSD Co. Ltd. (Japan), and Daiichi-Sankyo Co. Ltd. (Japan), respectively. All of the other chemicals used were reagent grade and commercially available.

2. OCT preparations

To determine the experimental conditions, the daily doses of OCT and DEX were assumed to be 300 μg and 4.0 mg, respectively. Based on continuous S.C. administration for 7 days at a flow velocity of 0.3 mL/h[3], the final concentrations of OCT and DEX were established as 41.7 μg/mL and 0.556 mg/mL, respectively.

1. Compatibility study with commercially available preparations

OCT was mixed with 3 DEX preparations (DEX SBS 2.0, DEX SBS 0.5, and DEX SBS 0) and diluted with physiological saline to achieve concentrations of OCT and DEX that were 41.7 μg/mL and 0.556 mg/mL, respectively. In these preparations, the final SBS concentrations in the mixed samples containing DEX SBS 2.0, DEX SBS 0.5, and DEX SBS 0 were 0.278, 0.0694, and 0 mg/mL, respectively. For consistency with conditions used in clinical practice, pH was not adjusted. Each sample was stored in a 1.5 mL microtube (Promega, Tokyo, Japan) under light-protected conditions, and the percentage of OCT in the sample was measured after 3 and 10 days.

2. Effect of pH

Each sample was diluted to an OCT concentration of 41.7 μg/mL with phosphate buffer at pH values of 4.0, 7.0, and 9.0. The pH was adjusted with sodium dihydrogen phosphate solution and disodium hydrogen phosphate. Each sample was stored in a 1.5 mL microtube (Promega) at room temperature under light-protected conditions, and the percentage of OCT in the sample was measured after 3 and 10 days.

3. Effect of SBS

To exclude the effect of pH, a solution containing 45 mg D-mannitol and 3.4 mg/mL lactic acid was mixed with saturated sodium hydroxide solution so that the pH value was 4.2 (OCT vehicle); this solution was used to dilute OCT. The composition of the OCT vehicle was similar to that of Sandostatin® excluding OCT. We investigated the stability of OCT when SBS free control and SBS containing (concentration of SBS: 0.3 mg/mL) samples were stored at room temperature or in a cool place (4°C). In these samples, the concentration of OCT was 41.7 μg/mL. Each sample was stored in a 1.5 mL microtube (Promega) under light-protected conditions, and the percentage of OCT in the sample was measured after 3 and 10 days.

3. HPLC analysis

For HPLC analysis[4], we used an LC-2010CHT HPLC system (Shimadzu Corporation, Kyoto, Japan) and LC Solution analytical software (Shimadzu Corporation). The injection volume was 10 μL and the measurement wavelength was 210 nm. Measurement was performed using a COSMOSIL5C18-MS II reverse-phase column (column diameter: 4.6 mm; column length: 150 mm) (Nacalai Tesque Co., Ltd., Kyoto, Japan) at room temperature. Mobile phases A (water:acetonitrile: 1 M tetramethylammonium hydroxide solution = 440: 50: 10) and B (water:acetonitrile: 1 M tetramethylammonium hydroxide solution = 190: 300: 10) were prepared. The pH was adjusted to 4.5 using phosphate solution. We used a gradient system in which the A to B ratio was linearly changed from 73: 27 to 55: 45 in 12 min after the start of analysis. Measurement was performed each three times, and data were shown as the means ± S.D. (n=3).

4. Assay line

OCT was diluted with the OCT vehicle for the preparation of a specific volume of standard solutions (OCT concentrations: 1, 5, 10, 20, and 50 μg/mL). Each standard solution (10 μL) was infused into the HPLC system, and an assay line was prepared using the peak heights (x) and concentrations (y).

5. Statistical analysis

Statistical comparisons were made using one-way ANOVA followed by Tukey’s test. P values of <0.05 were considered to indicate significance. OCT stability was defined as the maintenance of at least
Effect of sodium bisulphate on the stability of octreotide acetate

Palliative Care Research

Results

1 Compatibility study with commercially available preparations

The assay lines showed linearity at 1 to 50 μg/mL. When OCT was mixed with DEX-SBS 0, the percentage of OCT in the sample was 95% or more for 10 days after its preparation (96.7±0.2%). When OCT was mixed with DEX-SBS 0.5, the percentage of OCT in the sample was 90% or greater 3 days after its preparation (93.8±3.6%). However, the percentage significantly decreased to 85.1%±2.0% after 10 days (p<0.001). When OCT was mixed with DEX-SBS 2.0, the percentage of OCT in the sample was less than 90% three days after its preparation (89.9%±2.0%), which showed a significant decrease (p<0.001) (Table 1, Fig. 2). The pH values after preparation ranged from 5.0 to 7.0.

2 Effect of pH

At a pH value of 4.0, the percentage of OCT in the sample was 95% or more until 10 days after its preparation (97.7±7.7%), whereas at a pH value of 7.0, the percentage of OCT was less than 90% after 3 days (87.6±8.7%); however, no significant difference was found. At a pH value of 9.0, a significant decrease in the percentage of OCT in the sample was observed 3 days after its preparation (73.9±5.6%), which was reduced to 68.7±4.9% after 10 days (Fig. 3).

3 Effect of SBS

When SBS-containing OCT solution was stored at room temperature, the percentage of OCT in the sample significantly decreased to less than 90% three days after its preparation (84.4±4.0%, p<0.001, versus the initial concentration). When the solution was stored in a cool place, the percentage of OCT was 90% or more after 3 days (93.1±2.5%), but significantly decreased to 78.2±1.5% after 10 days (p<0.001, versus the initial concentration) (Fig. 4).

Furthermore, the retention time of OCT was 5.4 min. After 10 days, 90% of the initial OCT concentration was retained.

Table 1 Changes in the percentage of OCT after mixing with DEX

<table>
<thead>
<tr>
<th>Mixed drug</th>
<th>The percentage of OCT</th>
<th>The final SBS concentration (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEX-SBS 0</td>
<td>100±7.9</td>
<td>98.9±2.4</td>
</tr>
<tr>
<td>DEX-SBS 0.5</td>
<td>100±3.0</td>
<td>93.8±3.6</td>
</tr>
<tr>
<td>DEX-SBS 2.0</td>
<td>100±2.2</td>
<td>89.9±2.0</td>
</tr>
</tbody>
</table>

Data were shown as the means ± S.D. (n=3).
*p<0.001 (versus the initial concentration).

OCT: octreotide acetate, DEX: dexamethasone sodium phosphate, SBS: sodium bisulphate

Fig. 2 Serial compositional changes in octreotide acetate (OCT) and dexamethasone sodium phosphate (DEX) preparations

Fig. 3 Serial changes in the percentage of OCT in the sample with respect to pH values

*p<0.001 (versus the initial concentration)
Effect of sodium bisulphate on the stability of octreotide acetate

Fig. 4  Effect of sodium bisulphate (SBS) on the percentage of OCT in the sample

* $p<0.05$, ** $p<0.001$ (versus the initial concentration)

When SBS-containing OCT solution was stored at room temperature (RT) or in a cool place, the percentage of OCT in the sample significantly decreased to less than 90% after 3 or 10 days.

Discussion

This is the first study to elucidate the effect of SBS on the stability of OCT, with results revealing that compositional changes in OCT can be avoided by selecting SBS-free DEX preparations. No decrease in the percentage of OCT in the sample was observed for 10 days only when OCT was mixed with an SBS-free DEX preparation. In addition, pH was maintained at less than 7.0 for all of the mixed solutions, suggesting that SBS is an important factor influencing the percentage of OCT in a sample mixed with DEX. Moreover, the experiment in which the effect on OCT was investigated in the presence or absence of SBS also showed that the percentage of OCT in the sample serially decreased only in the presence of SBS, further supporting its involvement.

Several studies have shown that OCT stored in polypropylene syringes in a cool place (3°C) under light-protected conditions was stable for approximately 1 month \(^{14, 15}\). However, in the presence of SBS, it was impossible to prevent a decrease in the percentage of OCT in the sample at a pH value of 4.0, which is the pH at which OCT may be the most stable based on the results of our experiments investigating the effect of pH, even when the sample was stored in a cool place under light-protected conditions.

The SBS-related decrease in the percentage of OCT may be associated with disulphide bond cleavage and peptide hydrolysis. However, according to studies with insulin \(^{8, 16}\), the cleavage reactions of disulphide bonds with SBS proceed in the absence of denaturizing agents when inter-peptide chain bonds are detected. However, intra-chain disulphide bonds, as they are found in OCT, have a cyclic structure. Therefore, such reactions do not proceed in the absence of denaturizing agents. In addition, chromatograms showed several new peaks, suggesting that SBS promoted the hydrolysis of OCT, not the cleavage reactions of disulphide bonds as the insulin study. Thus, when mixing OCT with DEX preparations, an SBS-free DEX formulation should be used.

In conclusion, SBS-free DEX preparations should be selected when mixing OCT with DEX is necessary. In addition, when OCT is mixed with agents other than DEX preparations, whether the formula is suitable with respect to pH changes and the presence or absence of SBS should be evaluated. In some countries where SBS-free DEX preparations are available, OCT and DEX preparations may be administered as a mixture. Such measures that enable the administration of OCT and DEX as a mixture will decrease the frequency of punctures, which may reduce pain in patients who undergo combination therapy with these drugs. This study provides new information on the possible mechanisms involved in the compatibility of OCT with DEX preparations, and identifies a stable, mixed administration method for OCT and DEX preparations.

References


Potential conflicts of interest; The author(s) indicated no potential conflicts interest.
オクトレオチド酢酸塩の安定性に対する亜硫酸水素ナトリウムの影響—デキサメタゾン注射剤との配合変化試験

田辺 公一1), 大久保 純1), 池﨑 友明1), 北山 祥平2), 恒田 祐樹2), 新田 淑美3), 今村 理佐2), 藤 秀人2), 島田 雅也4), 村上 望4), 北澤 英徳1)

1) 富山県済生会高岡病院薬剤部, 2) 富山大学大学院医学薬学研究部(薬学)医療薬学研究室, 3) 富山大学大学院医学薬学研究部(薬学)薬物治療学研究室, 4) 富山県済生会高岡病院外科

【背景】オクトレオチド酢酸塩（以下, OCT）と併用頻度の高いデキサメタゾンリン酸塩（以下, DEX）製剤との配合変化の機序については不明な点が多い。本研究では pH および添加物である亜硫酸水素ナトリウム（以下, SBS）に着目し OCT の安定性を検討した。

【目的】本研究では pH および添加物である亜硫酸水素ナトリウム（以下, SBS）に着目し OCT の安定性を検討した。

【測定方法】SBS 濃度の異なる市販の DEX との混合溶液, およびリン酸緩衝液で pH4, 7 やび9 に調製した溶液, 並びに SBS 添加溶液の OCT 残存率を調製後 3 および 10 日後にそれぞれ HPLC (高速液体クロマトグラフィー) を用いて測定した。

【結果】SBS を含まない DEX との配合において混合後 10 日目まで OCT 残存率は 95%以上に維持されたが, 他剤ではいずれも 85%に有意に低下した。また, SBS との配合では 3 日で 90%未満へと OCT 残存率の有意な低下が認められた。

【考察・結論】OCT は SBS 共存下で加水分解により残存率が低下することが示唆され, SBS を含まない DEX 製剤を用いることでこの配合変化を避けることが明らかとなった。

Palliat Care Res 2013; 8(2): 177-83

Key words: オクトレオチド, デキサメタゾン, 亜硫酸水素ナトリウム, 配合変化, pH

表 1 DEX 製剤混合後の OCT 残存率

<table>
<thead>
<tr>
<th>混合した DEX 製剤</th>
<th>OCT 残存率</th>
<th>最終 SBS 濃度 (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>開始時</td>
<td>3 日目</td>
</tr>
<tr>
<td>DEX−SBS 0</td>
<td>100±7.9</td>
<td>98.9±2.4</td>
</tr>
<tr>
<td>DEX−SBS 0.5</td>
<td>100±3.0</td>
<td>93.8±3.6</td>
</tr>
<tr>
<td>DEX−SBS 2.0</td>
<td>100±2.2</td>
<td>89.9±2.0</td>
</tr>
</tbody>
</table>

結果は mean±SD で示した (n=3)。

*p<0.001 (versus the initial concentration).

OCT: octreotide acetate, DEX: dexamethasone sodium phosphate, SBS: sodium bisulphate
図2 OCTとDEX製剤との経時的配合変化
*p<0.001 (versus the initial concentration)

試料中のOCT残存量はSBSを含まないDEX製剤であるオルガドロン注(DEX-SBS 0)と混合した時のみ、調製後10日間で95%以上を維持した。

図3 pH別OCT残存量の経時的変化
*p<0.001 (versus the initial concentration)

OCTはpH4.0において最も安定であった。

図4 OCT残存量に対するSBSの影響
*p<0.05, **p<0.001 (versus the initial concentration)

SBSを含む溶液のOCT残存量は、室温保存時(RT)は3日後に、冷蔵保存時(4℃)は10日後に90%未満に有意に減少した。

図5 OCT 41.7μg/mL室温10日間保存後のクロマトグラム

A: SBSなし
B: SBS添加

New peaks